ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

durvalumab

Also written as “Durvalumab”, “MEDI4736” and “MEDI4736 (Durvalumab)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Carcinoma, Hepatocellular · Urinary Bladder Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 8 companies.

Drug pageDurvalumab: every studyMany companies study it; this page follows only the 100 they lead. All 482 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 27, 2020100 company-led studies, 45 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only8643 open or runningphase 4since May 27, 2020Sep 14, 2012Nov 30, 2026phase 2 · NCT07081633
Bristol-Myers Squibb70 open or runningphase 2since Feb 16, 2016Nov 25, 2015none ahead
AbbVieits history only20 open or runningphase 2since Feb 27, 2015Feb 27, 2015none ahead
Academic Thoracic Oncology Medical Investigators Consortiumits history only10 open or runningphase 2since Jul 22, 2016Jul 22, 2016none ahead
Advaxisits history only10 open or runningphase 2since Nov 6, 2014Nov 6, 2014none ahead
AGO Researchits history only11 open or runningphase 2since Nov 11, 2020Nov 11, 2020Jan 2028phase 2 · NCT04644289
Boston Scientificits history only11 open or runningphase 2since Sep 1, 2021Sep 1, 2021Jun 2027phase 2 · NCT05063565
Eli Lillyits history only10 open or runningphase 1since Oct 7, 2015Oct 7, 2015none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Biocompatibles UK, Daiichi Sankyo, Parexel, Apices Soluciones S.L., IQVIA Pty, Myriad Genetic Laboratories, PRA Health Sciences and Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 25, 2015First study: phase 1 study in Multiple MyelomaFirst studyNCT02616640 · 114 enrolled · United States, Canada, France and more
  2. Feb 16, 2016Phase 2 study in Multiple MyelomaNCT02685826 · 56 enrolled · United States, Canada, Denmark and more
  3. Apr 5, 2016Phase 2 study in LymphomaNCT02733042 · 106 enrolled · United States, France, Germany and more
  4. May 16, 2016Phase 2 study in Leukemia, Myeloid, AcuteNCT02775903 · 213 enrolled · United States, Austria, Belgium and more
  5. Jun 17, 2016Phase 2 study in Multiple MyelomaNCT02807454 · 37 enrolled · United States, Belgium, Canada and more
  6. Dec 19, 20162 phase 2 studiesNCT03000452, NCT03003520

TargetBeta

CD274 →read by rule
“A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
adebrelimabruleJiangsu HengRui Medicinephase 351
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 7 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03003520Lymphoma, Large B-Cell, Diffuse · United States, Austria, Denmark and more2CompletedApr 24, 202246
NCT03000452Multiple Myeloma · United States, Austria, Greece and more2CompletedSep 18, 201718
NCT02807454Multiple Myeloma · United States, Belgium, Canada and more2TerminatedJan 3, 202237
NCT02775903Leukemia, Myeloid, Acute · United States, Austria, Belgium and more2CompletedDec 31, 2018213
NCT02733042Lymphoma · United States, France, Germany and more2CompletedMar 6, 2019106
NCT02685826Multiple Myeloma · United States, Canada, Denmark and more2CompletedDec 15, 201756
NCT02616640Multiple Myeloma · United States, Canada, France and more1CompletedNov 23, 2018114

How it is read

Names in the registry

  • “Durvalumab”, 55 entries
  • “MEDI4736”, 20 entries
  • “durvalumab”, 7 entries
  • “MEDI4736 (Durvalumab)”, 3 entries
  • “MEDI4736 + tremelimumab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.